NURO Overview

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Wall Street analysts forecast NURO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NURO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NeuroMetrix Inc revenue for the last quarter amounts to 583.00K USD, decreased -55.77 % YoY.

NeuroMetrix Inc. EPS for the last quarter amounts to -0.87 USD, decreased -39.16 % YoY.

NeuroMetrix Inc (NURO) has 26 emplpoyees as of January 30 2026.

Today NURO has the market capitalization of 7.00M USD.